Related Experiment Video
Updated: May 22, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Systemic therapy in renal cell carcinoma: advancing paradigms
Oncology (Williston Park, N.Y.)
|May 2, 2012
Summary
Recent advancements offer new treatments for renal-cell carcinoma (RCC), a cancer once resistant to therapy. New agents targeting VEGF and mTOR are now standard, with more therapies in development.
Area of Science:
- Oncology
- Pharmacology
Background:
- Renal-cell carcinoma (RCC) was historically refractory to systemic treatments beyond cytokine therapy.
- The 21st century has witnessed significant progress in developing novel agents for RCC.
- Currently, six agents are approved by the US Food and Drug Administration (FDA) for RCC treatment.
Purpose of the Study:
- To review the current landscape of systemic agents for renal-cell carcinoma.
- To highlight emerging therapeutic targets and approaches in RCC treatment.
- To discuss the implications of new agent availability for clinical practice and research.
Main Methods:
- Review of FDA-approved agents and ongoing clinical trials for RCC.
- Analysis of current treatment paradigms, including VEGF and mTOR inhibitors.
- Discussion of future directions, including neoadjuvant/adjuvant therapy and combination strategies.
Main Results:
- Six FDA-approved agents are currently available for RCC.
- Next-generation vascular endothelial growth factor receptor (VEGFR) inhibitors, such as axitinib, show promise.
- VEGF and mTOR targeted therapies are now the mainstay of RCC treatment, with other molecular targets under investigation.
Conclusions:
- The development of novel agents has transformed RCC treatment from a refractory malignancy to one with multiple systemic options.
- New therapeutic strategies, including combination therapies and neoadjuvant/adjuvant approaches, are emerging.
- Challenges remain in optimizing treatment decisions and conducting research due to patient and resource limitations.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...